Zobrazeno 1 - 10
of 92
pro vyhledávání: ''
Autor:
Junji Uchino, Akira Nakao, Osamu Hiranuma, Yusuke Chihara, Masahiro Iwasaku, Takashi Kijima, Chieko Takumi, Yoshiko Kaneko, Takahiro Yamada, Masafumi Takeshita, Makoto Hibino, Yoshie Morimoto, Koichi Takayama, Kenji Morimoto, Takayuki Takeda, Tadaaki Yamada, Yasuhiro Goto, Hiroyuki Yamaguchi, Takashi Yokoi
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 161
Combination therapy of immune checkpoint inhibitors and chemotherapy is considered to be one of the standard treatment options for patients with advanced non-small-cell lung cancer (NSCLC). However, the clinical significance of immune checkpoint inhi
Autor:
S.F. Nyaw, T.H. So, K.O. Lam, T.C. Lam, C.L. Chiang, V.H. Lee, K.C. Tsang, F. Lim, Winnie Wai Lan Chan, F.M. Kong, A.W. Lee, J. Chik, H.C. Choi, J.O. Lau
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 159
Acquired resistance to TKI is an important unmet need in the management of EGFR mutated lung cancer. Recent clinical trial IMPower150 suggested that combination approach with VEGF inhibitor, check point inhibitor immunotherapy and platinum-based chem
Autor:
Elisabeth Oppliger Leibundgut, Sabine Schmid, Michael Mark, Ilaria Colombo, Oliver Gautschi, Gilles Godar, Martin Früh, Sacha I. Rothschild, Cristiana Sessa, Patrizia Froesch, David König, Corinne Rusterholz, Qiyu Li, Y. Metaxas
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 156
Background KRAS mutations are found in 20–25 % of non-squamous non-small cell lung cancer (NSCLC) and therapies targeting the RAS/MEK/ERK pathway are in development. We performed a multicenter open-label phase 1B trial to determine the recommended
Autor:
Michael Cabanero, Xuyang Song, Rosalyn A. Juergens, Penelope A. Bradbury, Phillip A. Dennis, John Hilton, P. Brown-Walker, Desiree Hao, John R. Goffin, Sebastien J. Hotte, Anna Tomiak, Gwyn Bebb, Scott A. Laurie, Andrew Robinson, Martin Smoragiewicz, Christian K. Kollmannsberger, I. Gauthier, Moustapha Tehfe, Xiaoqun Sun, Peter M. Ellis, Dongsheng Tu, Paul Wheatley-Price, Mihaela Mates, Janessa Laskin, Glenwood D. Goss, Lesley Seymour, Ming-Sound Tsao
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 143
This multicenter phase Ib study aimed to establish a recommended phase II dose for durvalumab (Du) ± tremelimumab (Tr) in combination with standard platinum-doublet chemotherapy. Eligible patients were enrolled into one of six dose levels (DL) of Du
Autor:
Riichiroh Maruyama, Kaoru Kubota, Noriyuki Masuda, Naoki Shimada, Masahiko Shibuya, Hideo Kunitoh, Takashi Seto, Masahiro Tsuboi, Tatsuo Ohhira, Koshiro Watanabe, Hiroaki Okamoto
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 141
Objective Adjuvant chemotherapy is standard of care for patients with completely resected stage IB, II and IIIA NSCLC. However, optimum chemotherapy regimen has not been determined. TORG0503 was undertaken to select a preferred platinum-based 3rd gen
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 133
Objective To explore the efficacy and safety of icotinib with chemotherapy as first-line therapy for advanced lung adenocarcinoma in patients with sensitive epidermal growth factor receptor (EGFR) mutations. Methods This prospective, randomized, cont
Autor:
Xiaozhen Liu, Yijun Jia, Ruoshuang Han, Caicun Zhou, Tao Jiang, Xiaoxia Chen, Limin Zhang, Jiawei Luo, Xuefei Li, Sangtian Liu, Sha Zhao, Meng Qiao, Chao Zhao, Jinpeng Shi
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 125
Background Although EGFR-tyrosine kinase inhibitors (EGFR-TKIs) are the standard treatment for patients with EGFR-mutant non-small-cell lung cancer (NSCLC), responses vary within individuals. The current study aimed to investigate whether serum level
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 122
Objectives The tyrosine kinase inhibitor crizotinib may affect renal function. The mechanism of this effect is not understood. We aimed to get more insight by measuring renal hemodynamics in patients treated with crizotinib. Materials and methods Ren
Autor:
Dong Wan Kim, Ramaswamy Govindan, Benjamin Besse, Byoung Chul Cho, Nathan A. Pennell, Prabhu Rajagopalan, Fabrice Barlesi, Goekben Koca, Matthias Ocker, Gérard Zalcman, Simon Langer, Grace K. Dy, Joo Hang Kim, Hendrik Nogai
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 123
Objectives This phase Ib/II study evaluated safety, pharmacokinetics, maximum tolerated dose (MTD), and efficacy of the pan-cyclin-dependent kinase inhibitor roniciclib with cisplatin-etoposide (CIS-ETOP) or carboplatin-etoposide (CARBO-ETOP) in pati
Autor:
Howard A. Burris, F. Anthony Greco, Davey B. Daniel, John D. Hainsworth, David R. Spigel, Tarek Mekhail, John D. Zubkus, Dianna Shipley, David M. Waterhouse
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 117
Purpose First-line treatment for patients with extensive-stage small cell lung cancer (SCLC) includes treatment with platinum-based combination chemotherapy. Amrubicin is a synthetic anthracycline with single-agent activity in relapsed/refractory SCL